source
- Novo reports $2.2 bn impairment hit as pipeline setbacks spur deal huntNovo's third‑quarter earnings disclosed a 15 billion Danish‑krone (about $2.2 bn) impairment charge, largely tied to recent clinical failures. The biggest components were a 4.6 bn‑krone loss from…
- Servier’s $1.55 B Edgewise muscular dystrophy trial fails to meet primary and secondary endpointsServier invested roughly $1.55 billion in Edgewise Therapeutics' muscular dystrophy program and, five months after the deal, announced that the pivotal phase 2 trial in Becker muscular dystrophy di…